abiraterone,olaparib
astrazeneca,merck
['crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'propel']
final os for propel: abi + olap vs abi + pbo in 1l mcrpc #gu23 abi + olap vs abi + pbo: os: hr 0.81, 95% ci 0.67-1.00 (47.9% mature) os hrrm: hr 0.66, 95% ci 0.45-0.95 os non-hrrm: hr 0.89, 95% ci 0.70-1.14 tfst: hr 0.76, 95% ci 0.64-0.90 pfs2: hr 0.76, 95% 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday